S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Darwin Global Management/Q1 2021

Darwin Global Management

Period: Q1 2021 Β· Filed: 2021-05-17
View on SEC EDGAR β†—
AUM
$510M
Total portfolio value
Positions
12
Reported securities
Top Holding
XLRN
40.0% $204.1M
QoQ Changes
+3 / -3
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 12 positions

⚠️ Performance % calculated from filing date ( 2021-05-17) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
XLRNACCELERON PHARMA INC$204.1M39.97%β€”β€”
40.0%
BBIOBRIDGEBIO PHARMA INC$128.8M25.21%$61.60$77.19+25.3%
25.2%
FATEFATE THERAPEUTICS INC$113.0M22.12%$82.45$2.92-96.5%
22.1%
RLAYRELAY THERAPEUTICS INC$27.1M5.30%$34.57$18.65-46.0%
5.3%
ARVNARVINAS INC$9.3M1.82%$66.10$8.39-87.3%
1.8%
MGNXMACROGENICS INC$9.1M1.78%$31.85$4.71-85.2%
1.8%
GBIOGENERATION BIO CO$6.2M1.22%β€”β€”
1.2%
KROSKEROS THERAPEUTICS INC$5.3M1.05%$61.55$11.26-81.7%
1.1%
CCCCC4 THERAPEUTICS INC$5.2M1.01%$36.99$4.30-88.4%
1.0%
IMVTIMMUNOVANT INC$1.1M0.21%$16.04$38.79+141.8%
0.2%
INBXINHIBRX INC$1.0M0.20%β€”$97.58
0.2%
FULCFULCRUM THERAPEUTICS INC$0.6M0.11%$11.78$3.84-67.4%
0.1%

Quarter-on-Quarter Activity

Q1 2021 vs. Q4 2020

New Positions (3)

TickerIssuerNotionalSince Filing
RLAYRELAY THERAPEUTICS INC$27.1M-46.0%
MGNXMACROGENICS INC$9.1M-85.2%
KROSKEROS THERAPEUTICS INC$5.3M-81.7%

Exited Positions (3)

TickerIssuerNotional
MRTXMIRATI THERAPEUTICS INC$57.3M
SRPTSAREPTA THERAPEUTICS INC$19.6M
STOKSTOKE THERAPEUTICS INC$0.4M

Increased (6)

TickerIssuerNotionalShares Ξ”Since Filing
ARVNARVINAS INC$6.3M+299.2%-87.3%
BBIOBRIDGEBIO PHARMA INC$81.6M+215.3%+25.3%
XLRNACCELERON PHARMA INC$84.0M+60.4%
FATEFATE THERAPEUTICS INC$26.3M+43.8%-96.5%
INBXINHIBRX INC$-0.2M+36.1%
GBIOGENERATION BIO CO$0.7M+11.2%

Trimmed (3)

TickerIssuerNotionalShares Ξ”Since Filing
IMVTIMMUNOVANT INC$-8.2M-67.0%+141.8%
CCCCC4 THERAPEUTICS INC$-2.4M-38.7%-88.4%
FULCFULCRUM THERAPEUTICS INC$-0.1M-18.7%-67.4%
← Back to Hedge Funds